Genentech, a member of the Roche Group, recently presented two abstracts on the company’s product Esbriet (pirfenidone), an oral drug developed for the treatment of pulmonary fibrosis (PF), at the American College of Chest Physicians Annual Meeting (CHEST 2015), held Oct. 24–28 in Montreal, Canada. Both abstracts were…
Genentech’s PF Drug Esbriet Shown To Lower Mortality Rates in New Study
Esbriet (pirfenidone, Genentech) is an anti-fibrotic drug developed as a therapy for pulmonary fibrosis (PF), and was one of the first two drugs to receive approval for PF treatment in the United States. New data on Esbriet was recently presented by Dr. Steven Nathan, Medical Director, Advanced Lung Disease…
Learn more about Idiopathic Pulmonary Fibrosis: https://bit.ly/1QiRmr3…
Clinical trials are well-designed studies that collect information about new treatments for diseases and disorders. Most of the time, this means medications but clinical trials can also test other things such as stem cell therapies, surgical techniques, tests for diagnosis, medical devices and others. In particular, clinical trials focus on…
The Pulmonary Fibrosis Foundation (PFF) recently announced that the number of scientific poster presentations on idiopathic pulmonary fibrosis (IPF) and interstitial lung diseases (ILD) to be displayed at the upcoming PFF Summit 2015: From Bench to Bedside in Washington, D.C., reached a record. The PFF Summit 2015: From…
Help raise awareness for this serious and devastating disease. Learn more about Pulmonary Fibrosis: https://bit.ly/1lfMsiZ…
Sixty-six year old Dan Castner was living life to the fullest when he started experiencing difficulties in breathing. While he worked in the outdoor industry for more than 40 years and was used to biking, climbing, camping, skiing and hiking, in March of 2012 his life completely changed. Castner was…
1. Lung Stem Cell Spheroids Could Offer Cheap, Rapid Pulmonary Fibrosis Therapy 2. Genentech to Help Lead Pulmonary Fibrosis Foundation Programs 3. IPF Experts Discuss Disease Diagnosis and Treatment at CHEST 2015…
The Pulmonary Fibrosis Foundation (PFF) recently announced in a press release a five-year collaboration with Boehringer Ingelheim to support PFF programs dedicated to the improvement of the clinical outcome in patients with pulmonary fibrosis (PF), increase awareness about the disease, and offer advance care, disease education and…
In a recent study entitled “Down-regulation of USP13 mediates phenotype transformation of fibroblasts in idiopathic pulmonary fibrosis,” a team of researchers investigated the differences in gene expression in fibroblast foci in patients with idiopathic pulmonary fibrosis (IPF). They found that the expression of a particular gene, USP13, was…
